Safer Personalised Cancer Treatment Digital Follow-up

Summary

The goal of this clinical trial is to investigate patient harm/ adverse events, overall survival and health related quality of life under treatment with immunotherapy medication in cancer patients when they are followed up by a personalized digital program where the patients report symptoms directly to health care personnel. The main questions the clinical trial aims to answer are: * How often and how severe are immunotherapy related adverse events/ side effects when patients are followed up by a digital personalized patient-reporting system compared to standard follow-up? * How are life quality and survival affected for patients followed up by a digital personalized patient-reporting system compared to follow-up standard follow-up?? Participants under immunotherapy cancer treatment will be followed up by a digital patient reporting program in one group, and compared to a group of cancer patients receiving the same treatment, but with standard follow-up without a digital program in another group. Researchers will compare the two groups to see if there any differences in how many patients who develop immunotherapy related patient harm and how long the patients live.

Eligibility

Inclusion Criteria:

* Above 18 years of age
* Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification
* Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications.

Exclusion Criteria:

* Hematological cancer
* Gynecological cancer

Conditions2

Browse More Trials